Pertussis Prophylaxis Guidelines

Vaccination Strategy (CDC)

• All adolescents and adults should receive a single dose of Tdap to replace their next scheduled Td booster, with priority for individuals who have or anticipate close contact with infants < 12 months of age. 1
• Adolescents and adults aged 11–64 years should receive one dose of Tdap even if their last Td was given less than 10 years ago, especially when there is increased risk of pertussis exposure or contact with high‑risk individuals. 1
• The interval between Td and Tdap may be as short as 2 years; shorter intervals are acceptable when the benefit of pertussis protection outweighs the risk of local reactions. 1
• Healthcare personnel with direct patient contact should receive Tdap as soon as feasible, prioritizing those who care for infants < 12 months. 1
• Women of child‑bearing age who might become pregnant should receive Tdap before conception when possible, because roughly 50 % of U.S. pregnancies are unplanned. 1
• If Tdap was not administered during pregnancy, it should be given immediately postpartum before hospital discharge; breastfeeding does not contraindicate the vaccine. 1
• Parents, grandparents < 65 years, childcare providers, and all adults with close contact to infants < 12 months should receive Tdap at least 2 weeks before beginning contact with the infant. 1

Antibiotic Chemoprophylaxis (CDC)

• All household and close contacts of a pertussis case should receive macrolide prophylaxis within 21 days of exposure, with azithromycin preferred because of superior tolerability and shorter treatment duration. 2
• Priority groups for post‑exposure prophylaxis include all household members, infants < 12 months (especially < 4 months), pregnant women in the third trimester, and healthcare workers with known exposure. 2
• The decision to provide prophylaxis weighs the infectiousness of the index case, intensity of exposure, risk of severe disease in the contact, and potential for secondary transmission to high‑risk individuals. 2
• Pertussis secondary‑attack rates exceed 80 % among susceptible household contacts, making prophylaxis essential even for vaccinated individuals who can still become infected and transmit disease. 3

Recommended Regimens (CDC)

• Alternative agents:
  
  • Clarithromycin – 7.5 mg/kg (max 500 mg) twice daily for 7 days in children; 500 mg twice daily for 7 days in adults. 2
  • Trimethoprim‑sulfamethoxazole – acceptable for patients > 2 months when macrolides are contraindicated. 2

Special Populations

• For infants < 1 month, azithromycin is strongly preferred over erythromycin because erythromycin is associated with a markedly higher risk of infantile hypertrophic pyloric stenosis (IHPS). 2
• Infants < 1 month receiving any macrolide must be monitored closely for IHPS and other serious adverse events. 2
• Pregnant women receive the same antibiotic regimens as non‑pregnant adults; macrolides are considered safe during pregnancy. 3
• For infants 1–5 months, azithromycin or clarithromycin are first‑line agents based on demonstrated in‑vitro activity and safety profiles, despite lack of FDA licensure for this age group—the benefit of preventing severe disease outweighs medication risks. 2

Timing and Effectiveness

• Prophylaxis must be initiated within 21 days of exposure; administration during the first 21 days after the index case’s cough onset can prevent symptomatic infection in contacts. 2
• The goal of prophylaxis is eradication of Bordetella pertussis from the nasopharynx of both symptomatic and asymptomatic carriers to prevent secondary transmission. 5
• Asymptomatic contacts who receive prophylaxis may continue normal activities, including work; routine laboratory testing is not required—clinical monitoring suffices. 3

Infection‑Control Measures (Praxis)

• Confirmed or suspected pertussis patients should remain in respiratory isolation for 5 days after starting appropriate antibiotics; if antibiotics cannot be given, isolation must continue for 21 days from cough onset. 5
• In healthcare facilities, place pertussis patients in private rooms or cohort them with other pertussis cases, and healthcare workers should wear surgical masks when within 3 feet of the patient. 5
• Healthcare workers who cannot receive prophylaxis should be excluded from caring for children < 4 years for 7–14 days post‑exposure if required by state law. 3

Common Pitfalls and Caveats

• Do not withhold prophylaxis based on vaccination status—vaccine‑derived immunity wanes after 5–10 years, and vaccinated individuals can still contract and transmit pertussis. 5
• Do not delay prophylaxis while awaiting laboratory confirmation; the 21‑day window is critical, and secondary‑attack rates are extremely high. 3
• Avoid erythromycin in infants < 6 months due to its strong association with IHPS; azithromycin presents a substantially lower risk. 2
• Antibiotic prophylaxis provides only short‑term protection against transmission; it does not confer lasting immunity, which requires vaccination. 3
• Neither vaccination nor natural infection provides lifelong immunity; protection wanes over time, making booster vaccination and prompt prophylaxis essential strategies. 5
• Erythromycin and clarithromycin inhibit cytochrome P450 enzymes and can interact with other medications; azithromycin does not have this interaction, making it safer in patients on multiple drugs. 2